SML3594

Masitinib

≥98% (HPLC)

• Sinónimos: 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, AB1010
• Fórmula empírica (notación de Hill): C₂₈H₃₀N₆OS
• Número de CAS: 790299-79-5
• Peso molecular: 498.64
• Número MDL: MFCD09954132
• Código UNSPSC: 12352200
• NACRES: NA.77

Propiedades

• Nivel de calidad: 100
• Ensayo: ≥98% (HPLC)
• Formulario: powder
• color: white to beige
• solubilidad: DMSO: 2 mg/mL, clear
• temp. de almacenamiento: 2-8°C
• cadena SMILES: CC1=CC=C(NC(C2=CC=C(CN3CCN(C)CC3)C=C2)=O)C=C1NC4=NC(C5=CN=CC=C5)=CS4
• InChI: 1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)
• Clave InChI: WJEOLQLKVOPQFV-UHFFFAOYSA-N

Descripción

Acciones bioquímicas o fisiológicas

Masitinib is a protein tyrosine kinase inhibitor that selectively targets stem cell factor receptor c-kit in particular and also PDGFRalpha/beta and Lyn. It is more potent and selective for c-kit than imatinib (Gleevec). Masitinib has antineoplastic and anti-inflammatory activity. It inhibits the survival, migration and activity of mast cells, key components of the inflammation response. It is used to treat mast cell tumors in dogs and is in clinical trials for human use in rheumatoid arthritis, asthma, and as an adjuct therapy for Alzheimer′s disease.

c-kit/PDGF receptor tyrosine kinase inhibitor

Información de seguridad

• Pictogramas: GHS08,GHS07
• Palabra de señalización: Warning
• Frases de peligro: H302,H361d,H373
• Consejos de prudencia: P202 - P260 - P264 - P280 - P301 + P312 - P308 + P313
• Clasificaciones de peligro: Acute Tox. 4 Oral - Repr. 2 - STOT RE 2
• Código de clase de almacenamiento: 11 - Combustible Solids
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable